

## ASSIGNMENT FOR PATENTS

Be it known that I/we, the undersigned, as inventor(s) of the subject matter contained in the patent application entitled:

**‘Composition containing cannabinoids with improved availability’**

as filed in the USA on August 8, 2017 as No 62/542,459 and extended as PCT/IB2018/000862 on August 7, 2018

(the “Invention”),

do hereby state that, according to my working contract, or an assignment between the inventor and the recipient, any and all rights arising from the Invention specified herein lawfully belong to the below named Recipient, and to the extent not previously done so by any prior assignment by me/us or operation of law, I/we do hereby confirm that I/we have assign and transfer, to the below mentioned Recipient as of the filing date of the Invention for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the full and exclusive worldwide right, title and interest in and to the Invention, including the right to claim priority, to sue and collect for past, present and future infringement, unto, :

**Creso Pharma Switzerland GmbH**  
**Alte Steinhauserstrasse 10**  
**6330 CHAM**  
**Switzerland**


(so-called « The Recipient »)

and its successors and assigns.

I/we further state and declare that the Recipient is fully entitled to: (a) make the patent/utility model/design application in its own name as from the time of its filing; and (b) use, make profit, assign or dispose of the Invention without necessity of any ratification, consent, endorsement on my/our part.

All of the above is true notwithstanding the insertion of my/our name(s) in any document related to such Invention; provided, however, that without any prejudice to the statements made herein, I/we, the inventor(s), wish to be mentioned and identified as the inventor(s) in any corresponding patent/utility model/design registration(s).

This assignment takes effect from the initial filing date of the Invention according to agreements in force prior that date between the inventors/applicants and the Recipient.

| Printed Name           | Date     | Signature                                                                            |
|------------------------|----------|--------------------------------------------------------------------------------------|
| HALPERIN WERNLI Miriam | 6.9.2018 |  |
| WERNLI Jorge           | 6.9.2018 |                                                                                      |
| TREPP Gian Batista     | 6.9.2018 |                                                                                      |

For Creso Pharma Switzerland GmbH

Date : 6.9.2018

  
Dr Miriam Wernli Halpérin (CEO)

## ASSIGNMENT FOR PATENTS

Be it known that I/we, the undersigned, as inventor(s) of the subject matter contained in the patent application entitled:

**‘Composition containing cannabinoids with improved bioavailability’**

as filed at the WIPO as PCT/IB2018/000862 on August 7, 2018

(the “Invention”),

do hereby state that, according to my working contract, or an assignment between the inventor and the recipient, any and all rights arising from the Invention specified herein lawfully belong to the below named Recipient, and to the extent not previously done so by any prior assignment by me/us or operation of law, I/we do hereby confirm that I/we have assign and transfer, to the below mentioned Recipient as of the filing date of the Invention for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the full and exclusive worldwide right, title and interest in and to the Invention, including the right to claim priority, to sue and collect for past, present and future infringement, unto, :

**Creso Pharma Switzerland GmbH  
Alte Steinhäuserstrasse 10  
6330 CHAM  
Switzerland**



(so-called « The Recipient »)

and its successors and assigns.

I/we further state and declare that the Recipient is fully entitled to: (a) make the patent/utility model/design application in its own name as from the time of its filing; and (b) use, make profit, assign or dispose of the Invention without necessity of any ratification, consent, endorsement on my/our part.

All of the above is true notwithstanding the insertion of my/our name(s) in any document related to such Invention; provided, however, that without any prejudice to the statements made herein, I/we, the inventor(s), wish to be mentioned and identified as the inventor(s) in any corresponding patent/utility model/design registration(s).

This assignment takes effect from the initial filing date of the Invention according to agreements in force prior that date between the inventors/applicants and the Recipient.

| Printed Name | Date       | Signature                                                                             |
|--------------|------------|---------------------------------------------------------------------------------------|
| HUBER Silvia | 29.8.18    |  |
| MADEA Franco | 29.08.2018 |  |

For Creso Pharma Switzerland GmbH

Date : 6.9.2018

  
Dr Miriam Wernli Halpérin (CEO)